Kevin Xu is currently serving as the Chairman & CEO of ClinChoice Medical Development Ltd – a global clinical stage CRO powering biotech innovation across US, China, EU and other APAC markets with end-to-end clinical development solutions. Previously, Kevin was a Managing Director at Goldman Sachs, where he built and led the firm’s Asia-Pacific Healthcare & Life Science Investing business for over 15 years. During his tenure, he directed high-impact investments across biotech, pharma, medtech, CROs/CDMOs, digital health, and AI-driven life science platforms, backing industry-leading innovators. Kevin holds an MSc in Neuroscience and Clinical Psychology from King’s College London’s Institute of Psychiatry, Psychology & Neuroscience, a Master of Finance from the University of Cambridge, and a B.S. from the University of Maryland. He also serves as the Queens’ Alumni Ambassador for Strategic Partnerships at the University of Cambridge. and a B.S. from the University of Maryland. He also serves as the Queens’ Alumni Ambassador for Strategic Partnerships at the University of Cambridge.

Zhou Tong’s research focuses on the mechanism of broad-spectrum antibody generation and in vitro antibody engineering. He established a microbial surface antibody display and screening platform based on phages, yeasts, and bacteria, and further integrating microfluidic systems, developed a high-throughput protein genotyping and rapid functional labeling system via microdroplet reactions, enabling high-throughput screening of multi-species antibody libraries and solving the microbial antibody display system’s low reproducibility. He co-founded a rare antibody discovery platform based on the “human distant-source immune animal model” with Ocean University of China, addressing the inability to generate antibodies against low-immunogenicity targets in humans and traditional mammalian models. He also collaborated with the National Microbial Data Center to build an antibody digital database (covering human, cotton rat, shark, etc.) and a modification hotspot prediction algorithm system, and further developed an AI-assisted antibody interpretation and prediction system based on antibody generation rules. These platforms strongly supported monoclonal identification and reshaping of multiple detection/therapeutic antibodies. He has co-authored 27 SCI papers, with 6 published as first/corresponding author in PNAS, Cell Reports, Nature Communications, and Nucleic Acids Research in recent five years, and holds 18 authorized national invention patents. His “Dia-19 bispecific antibody” for broad-spectrum COVID-19 prevention obtained national clinical trial approval in February 2024 (2024LP00386).

She has previously worked for the Bureau of Shanghai World Expo Coordination and Alibaba, providing services to international enterprises and academic institutions such as Baosteel, Infosys (India), and Wageningen University (Netherlands). She has managed and operated biotechnology industrial parks spanning over 1 million square meters, and served biopharmaceutical and bio-manufacturing companies including Zenshine Pharma, Zhejiang Guobang Pharma, Qihan Biotech, Asta Biotech, and Gancao Doctor. She is dedicated to “empowering scientists, accelerating future development”

Mr. Tang Ming is the Executive Director and Chief Executive Officer of YNBY International Limited, bringing over 25 years of extensive experience in international market development. He specializes in formulating global strategies, establishing and leading local teams, and navigating regional regulations and business ecosystems to successfully launch new ventures. With deep expertise spanning marketing and sales, research and development, supply chain management, and go-to-market (GTM) execution, Mr. Tang has worked across Europe, North America, and the Asia-Pacific regions, collaborating with top-tier clients across diverse industry verticals.

Xinmei Shen is a reporter with the South China Morning Post’s technology desk covering topics including AI, digital assets and biotech. Previously she produced multimedia stories at the Post’s technology news platform Abacus and was a graduate of the University of Hong Kong.

Amber Tong is a reporter at Bloomberg News covering Chinese and Asian biotech and pharma companies – and the growing role they play on the global stage. She has written extensively about the aspirations and challenges of China’s innovative drugmakers, the evolution of the complex Chinese healthcare market and the dynamic relationship between China and multinational pharmaceutical giants. A trusted voice in the sector, her work has been cited by industry insiders and media publications. Previously, Amber was a senior editor at Endpoints News.

Scott Cai, Managing Director of Prosperity 7 in China, with 20 years of investment experience ranging from venture capital to strategic investments. Before Prosperity 7, he served as the Group Vice President in Baidu and TAL, leading strategic investment and corporate funds. Prior to that, he was a Partner at SAIF, a leading venture capital fund in Asia, focusing in TMT investment and serving as President in a RMB fund. Earlier, he was a management consultant with A.T. Kearney.
He obtained his MBA from Harvard Business School and BS from Tsinghua University.

Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine, a leading clinical-stage biotechnology company pioneering next-generation generative AI and automated platforms for drug discovery. Repeatedly nominated for the Clarivate Analytics Highly Cited Researchers list, Dr. Zhavoronkov is an internationally recognized innovator in artificial intelligence for life sciences. Since 2014, he has developed critical technologies in generative AI and reinforcement learning for creating novel molecular structures and synthetic biological data. He also pioneered the application of deep learning techniques, including transformers, for predicting human biological age, transfer learning from aging into disease, target identification, and signaling pathway modeling. Dr. Zhavoronkov spent his early career in senior roles at ATI Technologies, which was acquired by AMD, before transitioning to biotechnology. He has published over 200 peer-reviewed papers and authored three books. In addition to his role at Insilico, Dr. Zhavoronkov serves on the editorial boards of several top journals and co-chairs the Annual Aging Research and Drug Discovery conference, the world’s largest event on aging research. He is also an adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

As the Associate Director of Therapeutics at HKSTP, Dr. Weng Li leads the account management of Therapeutics companies and Advanced Therapy Products (ATP) initiatives. She is also spearheading the Clinical Translational Catalyst programme, which aims to drive the clinical translation of biotech companies through funding support and more effective engagement with comprising clinicians, CROS, etc., through the HKSTP Clinical Professional Network. Weng Li sits on the HKSTP Clinical Research Ethics Committee and Joint Management Committees with HKU and CUHK ATP collaboration to establish PIC/S GMP facilities. Weng Li obtained her PhD in Pharmaceutical Technology from University College London and MBA from Imperial College London. She then worked at GlaxoSmithKline in the United Kingdom, serving as Lead Chemometrician in the New Product Development division. Weng Li was the Senior Research Director at Athenex HK prior to joining HKSTP.

Dr. Feng Ren is the Co-CEO and CSO of Insilico Medicine, He earned his Ph.D. in Chemistry from Harvard University in 2007 and embarked on a distinguished career in biopharmaceutical innovation. He began at GlaxoSmithKline (GSK), where he spent a decade advancing drug discovery and development. In 2018, Dr. Ren joined Medicilon, a global contract research organization (CRO), as Senior Vice President and Head of Drug R&D Services, overseeing operations in both the Chemistry and Biology Departments with a team of over 600 chemists and biologists. Dr. Ren transitioned to Insilico Medicine in 2021 as Chief Scientific Officer (CSO), where he assumed responsibility for advancing internal pipelines and fostering external collaborations in drug discovery and development. His exceptional contributions and leadership were recognized with a promotion to Co-CEO in June 2022. Under his guidance, Insilico R&D team successfully developed 22 pre-clinical candidate compounds, with 10 molecules received IND clearance in therapeutic areas including fibrosis, inflammation, oncology, and anti-viral treatments. Dr. Ren also played a pivotal role in driving four out-licensing agreements for proprietary pipelines as well as forging numerous strategic R&D collaborations, collectively valued at more than $3.5 billion. Dr. Ren publishes over 70 peer-reviewed papers and over 100 patents.